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ABSTRACT
Purpose To examine if pulmonary P-glycoprotein (P-gp) is
functional in an intact lung; impeding the pulmonary absorp-
tion and increasing lung retention of P-gp substrates adminis-
tered into the airways. Using calculated physico-chemical
properties alone build a predictive Quantitative Structure-
Activity Relationship (QSAR) model distinguishing whether
a substrate’s pulmonary absorption would be limited by P-gp
or not.
Methods A panel of 18 P-gp substrates were administered
into the airways of an isolated perfused mouse lung (IPML)
model derived from Mdr1a/Mdr1b knockout mice. Parallel
intestinal absorption studies were performed. Substrate
physico-chemical profiling was undertaken. Using multivari-
ate analysis a QSAR model was established.
Results A subset of P-gp substrates (10/18) displayed pulmo-
nary kinetics influenced by lung P-gp. These substrates pos-
sessed distinct physico-chemical properties to those P-gp sub-
strates unaffected by P-gp (8/18). Differential outcomes were
not related to different intrinsic P-gp transporter kinetics. In
the lung, in contrast to intestine, a higher degree of non-polar
character is required of a P-gp substrate before the net effects
of efflux become evident. The QSAR predictive model was
applied to 129 substrates including eight marketed inhaled
drugs, all these inhaled drugs were predicted to display P-gp
dependent pulmonary disposition.
Conclusions Lung P-gp can affect the pulmonary kinetics of a
subset of P-gp substrates. Physico-chemical relationships de-
termining the significance of P-gp to absorption in the lung are
different to those operative in the intestine. OurQSAR frame-
work may assist profiling of inhaled drug discovery candidates
that are also P-gp substrates. The potential for P-gp mediated
pulmonary disposition exists in the clinic.
KEY WORDS efflux . isolated perfused lung . lung . MDR,
Mdr . physico-chemical . pulmonary absorption . P-glycoprotein
(P-gp) . QSAR . transporter
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INTRODUCTION
Alongside passive processes, active or facilitative transporters
may govern the permeability of biological barriers to drugs.
Following oral inhalation of drug, lung epithelial transporters
may impact upon a drug’s intra-luminal residence time and
delivery to pharmacological targets within the submucosal
compartment as well as absorption to the systemic circulation.
While there is increasing awareness of the range and pattern
of expression of transporters within lung tissue (reviewed in
(1,2)) the functional significance of transporters upon pulmo-
nary drug disposition is however less well understood. In par-
ticular, given the extent of knowledge within other barriers
comparatively little is known about the functional significance
of P-glycoprotein (P-gp) within the lung.
Evidence for P-gp expression within whole lung is available
at both the mRNA and protein level in humans (MDR1 gene)
and rodents (Mdr1a and Mdr1b genes); in rodent lungs the
Mdr1b transcript appears to be expressed in greater abun-
dance than the Mdr1a transcript (3,4). Whether by PCR
(4,5) or microarray (3) methods the lung displays relatively
lower levels of P-gp mRNA expression compared to other
biological barriers such as the ileum. However, the lung pos-
sesses significant cellular heterogeneity and it is the P-gp ex-
pression within lung epithelium itself, as well as potentially
within intra-luminal macrophage populations and pulmonary
capillary endothelium, which can be expected to be the most
impactful for the pulmonary disposition of inhaled drug.
Correspondingly, within fully intact lung tissue P-gp protein
expression is recognised at the luminal surface of bronchial/
bronchiolar epithelium (4,6–9) and within alveolar epithelium
(4). Further, there are a number of in-vitro studies using alve-
olar and bronchial primary epithelial cells (4,10), or continu-
ous lung epithelial cell lines (2,11,12), corroborating P-gp pro-
tein expression and reporting varying extents of polarised
transport functionality. Nevertheless, the impact of P-gp upon
the overall pulmonary absorption and disposition of airways
administered drugs is poorly understood, and requires inves-
tigation within lung models where tissue architecture and the
parallel processes of passive and active clearance mechanisms
from the airways are to a large extent preserved.
In 2003 as part of a broader QSAR pulmonary absorption
investigation Tronde et al. (13) reported upon the extent of
pulmonary absorption of the P-gp substrates losartan and
talinolol, respectively, 92% (t1/2absorption 5 min) and 81% (t
1/
2absorption 17 min) following their administration as nebulised
solutions into the airways of anaesthetised rats.While the study
was not explicitly addressing efflux transporter issues it led the
authors to speculate that such high absorption suggests P-gp
may have little, if any, influence on the pulmonary transport of
P-gp substrates. Although, as acknowledged by the authors, the
drug solutions were administered at mM concentrations (3.8
and 2.8 mM, respectively, for losartan and talinolol) which
may have saturated efflux transporter activity. In the few stud-
ies undertaken using intact lung models that have explicitly
addressed the impact of P-gp upon the absorption of substrates
from the airways discordant conclusions exist. In 2008
Manford et al. (14) reported the pulmonary absorption of the
P-gp substrate digoxin to remain unchanged in CF-1 mice
which display a spontaneous Mdr1a knockout phenotype, al-
though these mice retain expression of the Mdr1b gene.
However, the same group also showed in an isolated perfused
rat lung (IPRL) model that co-administration into the airways
of a P-gp inhibitor, GF120918, had no effect upon the pulmo-
nary absorption of digoxin (11). Concurrently a 2008 report by
Francombe et al. (15), also using an IPRL model, showed the
pulmonary absorption of the P-gp substrate rhodamine-123
(Rh-123) to be signif icantly increased by the co-
administration of GF120918. In a follow-up study this discor-
dance between digoxin and Rh-123 outcomes was explicitly
examined in both IPRL and isolated perfused mouse lung
(IPML) models (16). Again using GF120918 to modulate P-
gp activity the pulmonary absorption of Rh-123 was increased
by P-gp inhibition, whereas that for digoxin remained unaf-
fected; the same study also showed discordance of the effect of
P-gp upon the pulmonary absorption of the P-gp substrates
saquinavir (unaffected) and loperamide (affected).
The airway to pulmonary vasculature transport of P-gp
substrates will, as in other barriers and notably well document-
ed for the intestine, reflect a balance between a substrate’s
physico-chemical properties driving membrane affinity and
transmembrane movement rate versus the substrate’s exposure
and engagement with P-gp within the membrane. However,
given the lung’s recognised permeability for hydrophilic mol-
ecules we hypothesised that in the lung, in contrast to the
intestine, a higher degree of non-polar character is required
of any P-gp substrate before the net effects of P-gp efflux
become evident. Here we report current work exploring this
question by examining the pulmonary absorption of an 18-
member panel of P-gp substrates within an IPMLmodel using
lungs from genetic Mdr1a/Mdr1b (−/−) double knockout
mice. The intestinal permeability of the panel of substrates
Price et al.
was also studied using ileal segments from the same knockout
animals. P-gp binding studies and physico-chemical profiling
was undertaken to build an orthogonal PLS Discriminant
Analysis (oPLS-DA) model based solely upon calculated
physico-chemical descriptors for the substrates. This oPLS-
DA model displayed capacity to predict whether P-gp would
impact upon the absorption of airway administered substrates.
In this work we have identified a distinct relationship between
substrate physico-chemical properties and P-gp efflux opera-
tive in the lung. The work advances our understanding of the
impact of P-gp upon drug absorption from airways with po-
tential relevance to the clinical setting, and provides a QSAR
framework of physico-chemical characteristics that may assist
the profiling of inhaled drug discovery candidates that are also
P-gp substrates.
MATERIALS AND METHODS
Materials
Radiolabelled [14C]- or [3H]-mannitol and the P-gp substrate
[ 3H] -d i gox in we r e pu r cha s ed f r om Amer i c an
RadioChemicals (St. Louis, MO). The P-gp substrates GSK-
1, -2 and −3, and indacatero l were suppl ied by
GlaxoSmithKline (Stevenage, UK). Unlabelled P-gp sub-
strates also contributing to the test panel of compounds includ-
ed: acrivastine, erythromycin, mitoxantrone, monensin, puro-
mycin, saquinavir, chloroquine, colchicine, domperidone,
eletriptan, rhodamine-123 (Rh-123), salbutamol and
salmeterol, all obtained from Sigma Aldrich (Poole, UK). All
other chemicals and solvents were obtained from Sigma-
Aldrich or Fisher Scientific at the highest available purities.
Animals
Male wildtype CD-1 mice were obtained from Harlan, UK.
Male Mdr1a(−/−)/Mdr1b(−/−) knockout mice (FVB strain)
were from Taconic (USA) and cross bred in-house (Cardiff)
with wildtype Mdr1a(+/+)/Mdr1b(+/+) female B6 strain
mice. Genotyping of F2-F5 generations allowed the selection
of homozygous breeding pairs of FVB/B6 Mdr1a(−/
−)/Mdr1b(−/−) mice and establishment of the FVB/B6
knockout colony. Genotyping involved extraction of genomic
DNA from mouse tissue (DNeasy Mini Kit, Qiagen, Hilden,
Germany) according to manufacturer’s protocol. Genomic
DNA samples (2 ng) were amplified by PCR using
HotStarTaq DNA Polymerase kit (Qiagen) with a recipe of:
2.5 μL 10x PCR buffer (final MgCl2 of 1.5 mM); 0.5 μL
10 mM dNTPs; 0.125 μL DNA polymerase; 0.5 μL 10 μM
primer stock, and nuclease free water (Ambion, TX, USA) to
a 25 μL final volume. The reaction was maintained at 95°C
for 15 min followed by thermal cycling (35 cycles: 94°C for
1 min, 55 or 60°C for 1 min, 72°C for 1 min with a final
extension of 72°C for 10 min). DNA fragments were separat-
ed by gel electrophoresis (1.25% agarose, 80 V (6.5 V/cm) for
45 min) and visualised under UV light using EtBr staining
with a 1 kb + DNA ladder (New England Biolabs).
Primer sequences for the amplification ofMdr1a were pro-
vided by Taconic, primer sequences for the amplification of
Mdr1b were designed in-house against the murine Mdr1b se-
quence (GenBank ID 18669) and the sequence of the disrup-
tive neomycin cassette inserted to the Mdr1b gene sequence
(Supplementary Table S1).
At experimentation all mice weighed 25–35 g and were
housed under barrier conditions with 12 h light-dark cycles
at 21°C and 45–60% humidity, and with access to food and
water ad Libitum. Isolated organ experiments conformed to
schedule 1 with animals euthanised by high dose i.p. injection
of sodium pentobarbital (Euthatal®) prior to surgery. All oth-
er animal studies were ethically reviewed and carried out in
accordance with Animals (Scientific Procedures) Act 1986 and
the GSK Policy on the Care, Welfare and Treatment of
Animals.
Isolated Perfused Mouse Lung (IPML)
The pulmonary transport of the test panel of P-gp substrates
was studied using an IPML model as described previously
(16). Male mice (30 ± 3 g) were euthanised and the trachea
exposed and cannulated (mouse tracheal cannula of L -
20 mm, OD −1.3 mm, ID - 1.0 mm; Harvard Apparatus,
UK) with insertion of cannula to a distance of 2–3 mm short
of the first bifurcation. Abdominal and thoracic cavities were
exposed and the pulmonary artery catheterised and perfused
(recirculating mode at a rate of 1 mL.min−1 using a peristaltic
pump, Munipuls 3, Gilson, USA) with oxygenated, 95%O2 /
5% CO2, 37°C Krebs-Henseleit buffer supplemented with
4% w/v BSA. The atria and the lower half of the heart were
cut to allow the free flow of perfusate. The lungs were re-
moved and suspended vertically in a custom water-jacketed
glass thorax (Radleys, Essex, UK) maintained at 37°C.
Following a 5 min equilibration the lungs were then ventilated
throughout the experiment (0.3 mL of air, 70 breaths.min−1,
mechanical ventilator 501,718, Harvard, UK).
Compounds were administered into the IPML airway in a
volume of 25 μL (PBS pH 7.4) using a gas-tight stoplock
Hamilton syringe (1700 series) and involving the simultaneous
co-administration of a bolus volume of 250 μL air helping to
both inflate the lungs and provide more extensive and repro-
ducible distribution of drug to the lung lobes and periphery.
This dosing method results in a reproducible >94% deposi-
tion of dose to the lung lobes with the remaining (ca. 6%)
deposited in the tracheal cannula and trachea/major bronchi.
The individual lobar deposition of compound (expressed as a
% deposited dose) has also been shown to be proportional to
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the lobar mass (16). In each experiment IPML viability was
assessed over a 45 min window, confirmed by monitoring of
the absorption of the hydrophilic solute, mannitol, and post-
experiment measurement of the wet/dry weight ratio of the
lungs. IPML experiments were discarded (typically 1 in 10
preparations) where visible or quantitative evidence of pulmo-
nary oedema within the lungs was observed. Typically wet:dry
weight ratios averaged 3.32 ± 0.34 in freshly isolated lungs
compared to 3.23 ± 0.27 for lungs used in IPML experiments.
Similarly IPML experiments were discarded where co-
instilled radiolabelled mannitol absorption was >65% of de-
posited dose over the 30 min experimental period.
To avoid differential solvent effects, and irrespective of the
physico-chemical properties of each of the 18 P-gp substrates
within the panel, the 25 μL dose solutions administered into
the IPML airways all included a final concentration of 0.1%
DMSO. Non-radiolabelled P-gp substrates were all adminis-
tered at a dose of 1.25 nmoles (based on free drug) and equat-
ing to a concentration in the 25 μL dose solution of 50 μM.
Radiolabelled [3H]-digoxin was administered at a dose of 16
pmoles equating to a concentration of 0.64 μM. Included in
all dose solutions for every experiment was 0.22 μM [3H]-
mannitol as the hydrophilic paracellular marker used as an
indicator of intrinsic lung barrier integrity; [14C]-mannitol
was used in experiments involving [3H]-digoxin. All com-
pounds were confirmed to have negligible binding to the tub-
ing and glassware used in the IPML setup.
Bioanalysis
Following dosing of compound into the IPML airways serial
samples (250 μL) were collected for bioanalysis from the
10 mL recirculating perfusate reservoir. Each sample collect-
ed from the reservoir was replaced with an equal volume of
fresh warmed, oxygenated perfusate. Upon termination of the
experiment the dose solutions, apparatus washings and per-
fusate samples were collected for mass balance calculations
enabling determination of the actual total dose delivered to
the lungs.
Radioactive compounds were directly analysed by liquid
scintillation counting. Volumes of 50 μL perfusate samples
were mixed with 3 mL of Scintisafe 3 Liquid Scintillation
Fluid (Fisher, UK) and transferred to vials for scintillation
counting using a TriCarb 2900TR (Packard Bioscience,
USA). Analysis for non-radiolabelled substrates involved
deproteinisation by precipitation with 2x volume of ice-cold
acetonitrile (ACN) or methanol (MeOH) to the sample follow-
ed by centrifugation (20,000 g 15 min at 4°C) with the
resulting protein-free supernatant undergoing analysis by
LC-MS or LC-MS/MS ESI + ve ionisation (Thermo
Finnigan LCQ Classic). Samples were analysed using a C-18
HPLC column (Kromasil, 100 Å pore, 3.5 μm particle size) at
30°C with a mobile phase (0.2 mL/min) comprising a various
gradients of solvent A: MeOH or ACN, and solvent B: H20 +
0.1% Formic Acid; MS/MS was used for domperidone,
mitoxantrone, monensin, saquinavir. Standard curves for all
compounds were prepared in perfusate and included as a
reference pre-dose perfusate that had been passed through
the IPML. At a concentration of 3 ng/mL (the set LLQ) all
analytes displayed a quantitation accuracy within ±13%and a
precision within 10%, but for most analytes these parameters
were considerably smaller than this (Supplementary
Table S2).
After accounting for the mass of compound removed at
each sample point, plots of the cumulative ‘%deposited dose
absorbed’ versus ‘time’ were generated and subject to nonline-
ar regression analysis according to a first-order absorption
one-compartment accumulating model (Eq. 1) to generate
estimates for the extent (F) and rate (Ka) of absorption from
the IPML airways to the recirculating perfusate. For each
compound preliminary studies had confirmed negligible loss
from the recirculating perfusate to lung tissue or to the IPML
tubing or glassware.
%Dose absorbed ¼ 100* F * 1−e−Ka*t  ð1Þ
The data was also subject to standard non-compartmental
analysis, specifically Area Under Curve (AUC0–30 min) of
‘%deposited dose absorbed’ versus ‘time’ (units: %Dose.min)
and reflecting for the exclusively accumulating perfusate
‘compartment’ the exposure arising from the IPML absorp-
tion process alone.
COMPOSITION OF P-GP SUBSTRATE TEST
COMPOUND DATA SET
The impact of a deficiency of P-gp upon the pulmonary ab-
sorption of the P-gp substrates digoxin (14) and rhodamine-
123 (15,16) had previously been explored in isolated perfused
lung models, as such these compounds represented the respec-
tive archetypes for Group A and Group B substrates (see be-
low). The remainder of the 18 member P-gp substrate panel
were selected on the basis of: (i) providing a diverse spectrum
of physico-chemical properties; (ii) inclusion of inhaled com-
pounds; (iii) availability of sensitive LC-MS/MS assays, and
(iv) evidence that all had demonstrated P-gp mediated efflux
within an accepted publishedmodel (17,18) or within in-house
models for the GSK compounds (unpublished data).
The outcomes of the IPML experiments allowed
categorisation of the test panel into Group A compounds
whose absorption was not affected in the IPML by /1b knock-
out, and Group B compounds (Table I) whose absorption was
increased in the IPML by Mdr1a/1b knockout; this
categorisation was then used in describing the outcomes from
all other experimental approaches.
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ABC Transporter Membrane ATPase Assay
The Gentest ATPase assay (Corning, Germany) was used to
investigate the binding kinetics of the panel of P-gp substrates
againstmembranes constituted to display humanMDR1,mouse
Mdr1a, mouse Mdr1b and mouse Bcrp. The assays measure the
accumulation of inorganic phosphate (absorbance at 800 nm)
produced in the breakdown of ATP to ADP. The assays are
an indirect measure of ABC transporter interactions and do
not distinguish between substrates or inhibitors. The assays were
used in accordance with themanufacturer’s protocol to calculate
(GraphPad Prism) the Michaelis-Menten parameters Km and
VMAX. For the assay test compounds were serially diluted to
produce an assay concentration range of 0–300 μM with the
kinetics of ATP turnover examined over 30 min at 37°C.
Computational Physico-Chemical Properties
The primary physico-chemical properties: cLogP, cLogD, H-
bond donors, H-bond acceptors, rotatable bond count, mo-
lecular volume and molecular weight were determined for the
test panel using the online ACD/Labs software with the
SMILES string for each substrate as the input. Polar surface
area and solvent accessible surface area were calculated using
ChemBio3D Ultra 11.0. The Abraham solvation descriptors
were calculated using an additive model based on molecular
fragments as previously described (19).
Immobilised Artificial Membrane (IAM)
Chromatography
IAM chromatography provided an experimental measure of
substrate membrane affinity and phospholipid interaction.
The IAM column (Regis Technologies Inc., Hichrom,
Reading, UK; IAM.PC.DD2 10 cm x 4.6 mm ID column)
was run under isocratic eluting conditions with the retention
of all compounds determined under three mobile phase con-
ditions: 10%, 20% and 30% acetonitrile in water, and from
which the theoretical retention time in 100% water was cal-
culated by linear regression. LogKIAM values were calculated
according to Eq. 2:
LogK IAM ¼ Log T r−T 0ð Þ
T 0
 
ð2Þ
where Tr and T0 are respectively the retention times of the
substrate in 100%water and of the unretained compound, i.e.
eluting within the solvent front of 75 s in all experiments.
Multi-Lamellar Liposome Vesicle (MLV) Partitioning
MLVs were formed as previously described (20). Briefly, solu-
t i on s o f 8 mg pho spha t i d y l c ho l i n e and 2 mg
phosphatidylglycerol in 10 mL chloroform were completely
dried to a lipid film (rotation under vacuum). MLVs were
formed by the addition of 1 mL of 25mMHEPES-Tris buffer
(pH 7.5) with gentle shaking for 4 h. The suspension was then
centrifuged at 6000 g for 15 min to pellet the vesicles and the
supernatant was removed. The MLVs were resuspended in
10 mL of PBS (pH 7.4) and stored at 4°C under nitrogen gas
overnight before partitioning experiments were performed.
The average lipid yield in the formed MLVs was estimated
by freeze drying and was 46 ± 8% (a value consistent with
Eytan et al. (20) studying MLV partition of P-gp substrates)
and generating an MLV suspension containing 10–15 μM of
phospholipid.
For partitioning experiments the MLV suspension was di-
luted 1000-fold in PBS (pH 7.4) with 990 μL transferred to a
microfuge tube into which 1 μg (10 μL) of P-gp substrate was
added. These preparations were then incubated at 37°C for
4 h under shaking conditions to allow equilibration of com-
pound between the lipid and aqueous fractions. The MLVs
were then pelleted and 100 μL of supernatant removed for
analysis by radiometric or LC-MS/MS methods as described
above. Partitioning into the MLVs was determined according
to Eq. 3:
MLV partitioning ¼ C0−CS½ 
.
C0 ð3Þ
where C0 is the initial compound concentration (1 μg/mL)
and CS is the compound concentration present in the aqueous
supernatant at the end of 4 h incubation.
Ussing Chamber Intestinal Permeability
Following isolation of the lung tissue for IPML experiments
the same animals were used to obtain Mdr1a/1b (+/+) and
Mdr1a/1b (−/−) intestinal tissue. The mouse Ussing chamber
experiments were performed as previously described by others
(21–23) including retention of the seromusculature layer
whose removal can easily damage the mouse intestinal muco-
sa. The presence of the seromusculature layer itself also pre-
serves the intramural neuromuscular connections and is re-
ported not to impact to any significant extent upon the per-
meability of hydrophilic or hydrophobic drug solutes (21).
The distal third (distal jejunum and ileum) of the mouse
small intestine was isolated and flushed with protein-free
Krebs-Henseleit buffer (pH 7.4) to remove faecal matter, after
which 1 cm length segments were cut (avoiding any visible
Peyer’s patches), opened longitudinally and mounted within
a vertical tissue diffusion chamber system (Harvard). The
bathing fluid for both mucosal and serosal surfaces (3 mL
volume in each chamber) comprised oxygenated Krebs-
Henseleit buffer maintained at 37°C (heating block) under
stirred conditions (gas flow manifold). The tissue was allowed
to equilibrate for 15 min after which transepithelial electrical
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resistance (TEER) was recorded (gas flow temporarily halted)
using NaviCyte Ag/AgCl electrodes and an Epithelial voltage
clamp (Harvard). Any intestinal segments presenting an initial
TEER of lower than 80 Ω.cm2 were discarded prior to the
experiment, likewise any segments whose TEER decreased by
more than 10% over the course of the experiment were ex-
cluded. The viability of such tissues preparations has been
shown to extend to 4 h.
The concentrations of the P-gp substrates dosed into the
Ussing chamber experiments were matched to those used in
the IPML experiments, e.g. for the non-radiolabelled sub-
strates the final concentration in the mucosal barrier chamber
was 50 μM in Krebs-Henseleit buffer. Following application
of the test compounds, serial samples (1000 μL) for analysis
were collected over a 180 min period from the serosal cham-
ber with the removed sample replaced with an equal volume
of fresh warmed and oxygenated buffer. Samples were subject
to radiochemical or LC-MS/MS bioanalysis as for the IPML
studies. Thereafter permeability coefficients were determined
according to Eq. 4:
ρ ¼ dM
dt
 .
A*C0
  ð4Þ
where dM/dt is the rate of transport observed across the
180 min experiment, A is the surface area of the intestinal
segment exposed in the experiment (0.12 cm2) and C0 is the
initial donor concentration of the compound.
Development of a QSAR Classification Model
To evaluate which physico-chemical properties were the main
drivers associated in determining whether compounds display
Group A absorption properties in the IPML (absorption not
affected by Mdr1a/1b knockout) or Group B properties (ab-
sorption increased in the IPML by Mdr1a/1b knockout) the
physico-chemical descriptors for the 18 substrate molecules
were used to build an orthogonal PLS Discriminant Analysis
(oPLS-DA) model (SIMCA v13.03, Umetrics AB). Thirteen
physico-chemical properties (Table I) that generally describe
lipophilicity, hydrogen bonding, size, shape, charge and atom
polarisability properties were calculated from the molecular
structures and used as the input descriptors of the model.
Statistical Analyses
The following statistical approaches were used in either
GraphPad PRISM or SPSS, and are described within the
individual Figure and Table legends: T-test for independent
samples; One-way AVOVA and Tukey post-hoc for compar-
isons of each mean with every other mean or Dunnett post-
hoc comparing every mean to control; Pearson Correlation
coefficient and for ranked correlations Spearman Correlation
coefficient, both two-tailed; Power Analysis for sample sizes.
Nonlinear regression was undertaken by WinNONLIN, and
PLS Discriminant Analysis (oPLS-DA) undertaken using
SIMCA.
RESULTS
Differential Absorption of P-Gp Substrates in the IPML:
Impact of P-Gp Knockout
We established a colony of FVB/B6 Mdr1a/1b (−/−) knock-
out mice where the complete disruption of both Mdr1a and
Mdr1b genes was conf i rmed by mul t ip lex PCR
(Supplementary Fig. S1A). The homozygous FVB/B6
Mdr1a/1b(−/−) knockout and strain matched wildtype
Mdr1a/1b(+/+) mice were used in IPML preparations as pre-
viously described (16), where the consistency of airway dose
and lobar pattern deposition of substrate as well as the viability
of the tissue barrier, had previously been confirmed.
The disruption of the Mdr1a/1b genes did not affect pul-
monary barrier permeability per se as evidenced by the airway
to perfusate absorption of the co-instilled paracellular probe
mannitol, the absorption of which remained unchanged be-
tween the Mdr1a/1b(−/−) and Mdr1a/1b(+/+) FVB/B6
groups (respectively, 43.2 ± 10.2% and 44.3 ± 9.4% of the
deposited dose absorbed by 30 min). Mannitol permeation in
the lungs of the FVB/B6mice was also comparable to that for
wildtype CD1 albino mice (Supplementary Fig. S1B). We
noted no differential effects of any of the compounds in the
panel to alter mannitol permeability.
Figure 1a shows a plot of the perfusate AUC0–30 min values
for the eight ‘Group A compounds, defined as such by their
absorption in the IPML remaining unaffected by Mdr1a/1b
knockout, and where digoxin served as the archetype com-
pound (Fig. 1a insert). Here the perfusate AUC0–30 min pa-
rameter reflects absorption across the pulmonary barrier into
what is a non-eliminating accumulating perfusate compart-
ment. A similar plot is shown for the ten Group B compounds
(Fig. 1b) where Rh-123 served as the archetype compound
(Fig. 1b insert). Only for the Group B compounds did the
deletion of Mdr1a/1b (−/−) result in significant increases
(37% to 93%) in pulmonary absorption (P-values 0.003 to
0.027, Supplementary Table S3). The corresponding perfus-
ate profiles for each of the Group A and Group B compounds
are shown in Supplementary Figs. S2 to S5, where significant
differences in the absorption profiles between the Mdr1a/1b
(−/−) and Mdr1a/1b (+/+) mice were seen for the Group B
compounds only.
The differential impact of Mdr1a/1b deletion between the
two groups of compounds appeared unrelated to the extent of
absorption per se. In Mdr1a/1b (+/+) lungs the average %
dose absorbed was 26.3% (95% CI of 20.5–31.9%) for the
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Group A compounds, while for Group B compounds the re-
spective value was 30.5% (18.9–42.3%) (P = 0.36). The ob-
served extent of absorption for all 18 compounds as well as
pharmacokinetic model estimates of bioavailability (F) are
shown in Supplementary Table S4. While the pharmacoki-
netic model fit represented the observed data well with model
estimates for ‘F’ showing low variance, the estimates for the
first-order absorption rate constant, ‘Ka’, were less reliable
(typically % CV of ca. 50%) and were not improved by ap-
plying different weighting to themodel parameters or bymore
complex models. The greater variance in the Ka parameter
probably reflected variability caused by the rapidly changing
perfusate concentrations at the early time points combined
with a limitation in collecting enough observations to accu-
rately determine the initial rate.
Comparative Interaction of Substrates with P-Gp
Membranes
All of the compounds used in the panel had previously been
identified through functional studies to be P-gp substrates.
Here we examined for differential P-gp binding kinetics within
a
b
Fig. 1 Impact of Mdr1a/1b (−/−)
knockout upon pulmonary
absorption of airway dosed P-
glycoprotein substrates: (a)shows
the cumulative absorption (defined
by AUC0–30 min calculated on drug
levels in the IPML recirculating
perfusate) for Group A compounds
in IPML preparations from Mdr1a/
1b(−/−) knockout mice (KO,
unfilled bar) and wild-type Mdr1a/
1b(+/+) mice (WT, filled bars).
Insert shows IPML absorption
profile for digoxin, the archetype
Group A compound; (b)shows the
cumulative absorption of Group B
compounds in IPML preparations
from Mdr1a/1b(−/−) knockout
mice (KO, unfilled bar) and wild-
type Mdr1a/1b(+/+) mice (WT,
filled bars). Insert shows IPML
absorption profile for Rh-123, the
archetype Group B compound.
Data represent mean ± S.D.,
n= 4 to 6 mice for each treatment
arm. * indicates statistical difference
at P < 0.05.
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the panel of compounds using ATP assays in artificial mem-
branes constituted by human (MDR1) and mouse (both
Mdr1a and Mdr1b) P-gp. Not surprisingly the assays indicated
all compounds to interact with P-gp with both the Km and
Vmax data for the 18 compound panel showing significant
correlations (P < 0.001, Pearson Correlation Coefficient)
across the MDR1, Mdr1a and Mdr1b membranes
(Supplementary Table S5). Importantly, no significant differ-
ence (P > 0.05) was found in any of the kinetic parameters
between the Group A and the Group B substrates (Fig. 2).
Additionally we studied the interactions of the compounds
with mouse breast cancer resistance protein (Bcrp). In the cur-
rent work we found the vast majority of the 18 compound
panel not to generate ATP turnover in the mouse Bcrp mem-
brane model (Supplementary Table S5). In addition to evi-
denced Mdr1a/1b interactions, only four of the compounds
also showed evidence of interactions with Bcrp. Namely two
Group A compounds - GSK1 and mitoxantrone, and two
Group B compounds - chloroquine and Rh-123. Indeed it is
for these very four compounds where some literature evidence
(varying in strength) supports BCRP/Bcrp interactions, either
as a substrate or inhibitor. An important point to make is that
the ATP assays should not be viewed as having direct quanti-
tative meaning to transport functionality in biological mem-
branes, rather it is a way of ranking the kinetics of interactions
for a subset of compounds against a given membrane model.
Differential Physico-Chemical Properties of P-Gp
Substrates
The discordance across our panel of compounds in respect to
the net effect of P-gp upon IPML absorption may reflect dis-
tinct differences in the compounds’ passive membrane inter-
actions. We first used computational approaches to determine
the physico-chemical properties and Abraham solvation de-
scriptors for each compound (Table I and Fig. 3a and b). The
Group A compounds possessed a distinctly more polar char-
acter, the very characteristics of P-gp substrates that, at least in
the intestine (24), would be indicative of substrates displaying a
slower transmembrane movement rate and be subject (all oth-
er things being equal) to a greater net effect of P-gp efflux. To
more fully define the capacity for hydrogen bonding interac-
tions we used a fragment-based approach to calculate
Abraham solvation descriptors (Fig. 3b). The Group A com-
pounds showed significantly greater (P < 0.05) Abraham acid-
ity and Abraham basicity values as well as Abraham polariz-
ability, all indicative of a greater strength of hydrogen-
bonding and a reduced affinity for biological membranes.
We next undertook IAM chromatography to experimen-
tally quantify molecule affinity with phospholipid membranes;
compounds showing a reduced extent of interaction with the
phospholipid stationary phase possessing a lower LogKIAM
value. As P-gp substrates all of the compounds were retained
on the IAM column, indicative of their capacity for phospho-
lipid interactions, however, consistent with the computational
descriptors the LogKIAM values for the Group A compounds
were significantly (P= 0.017) smaller than those for the Group
B compounds (Table II). We also examined partitioning of the
c ompou n d s w i t h i n p h o s p h a t i d y l c h o l i n e a n d
phosphatidylglycerol MLV liposomes, determining a
partitioning parameter reflective of both initial membrane
affinity of the compound and the compound’s transmembrane
movement rate across theMLV structure (20). Consistent with
the IAM chromatography the Group A compounds displayed
a significantly (P = 0.0003) reduced partitioning compared to
the Group B compounds (Table II). Not surprisingly these two
methodologies are recognised to be correlative (25), and in-
deed the current work also showed them as such (Pearson
Coefficient = 0.765; P = 0.0002) (Fig. 3c).
Fig. 2 Binding interactions of P-glycoprotein substrates assessed against hu-
man MDR1, and rodent Mdr1a andMdr1b: (a) comparative binding data for
Km (μM); (b) comparative binding data for Vmax (μM .min
−1); (c) comparative
binding data for Vmax/Km (min
−1). Data represents mean with associated 5%
to 95% confidence interval (CI) from three independent experiments, where
in each experiment any substrate was examined in duplicate across a 1–
300 μM concentration range.
QSAR in the Pulmonary Kinetics of P-Glycoprotein Substrates
Both Log KIAM and MLV partitioning reflect molecular
properties discriminatingmembrane interactions and, not sur-
prisingly, significant negative correlations were observed with
the calculated physico-chemical properties reflecting polarity.
For example, theMLV partitioning possessing strong negative
correlations with PSA (P = 0.005x10−7), H-Bond Total
(P = 0.001x10−6), Abraham Basicity (P = 0.001x10−4) and
H-Bond acceptor (P = 0.001x10−2).
Table II Experimental determination of membrane affinity by IAM column
chromatography and membrane partitioning in multi-lamellar vesicle (MLV)
liposomes. The 18 substrates are grouped into those molecules whose ab-
sorption in the IPML was unaffected by P-gp knockout (Group A) or those
molecules whose absorption in the IPML was increased by P-gp knockout
(Group B). Data represent the mean of four independent experiments. §
indicates significant difference by unpaired T-test between Group A and B at
P= 0.017 ¶ indicates significant difference by unpaired T-test between Group
A and B at P = 0.0003
LogKIAM MLV Partitioning
GROUP A Acrivastine 1.50 0.96
Digoxin 0.92 0.30
Erythromycin 0.88 0.46
GSK1 1.08 0.65
Mitoxantrone 1.13 0.59
Monensin 1.32 0.68
Puromycin 1.31 0.62
Saquinavir 1.24 0.45
Mean
± S.D.
1.17
±0.21
0.59
±0.20
GROUP B Chloroquine 1.43 0.95
Colchicine 1.30 0.86
Domperidone 1.33 0.92
Eletriptan 1.46 0.94
GSK2 1.29 0.86
GSK3 1.38 0.97
Indacaterol 1.23 0.92
Rh-123 1.30 0.82
Salbutamol 1.47 0.88
Salmeterol 1.60 0.80
Mean
± S.D.
1.38§
±0.11
0.89¶
±0.06
Fig. 3 Physico-chemical and membrane affinity parameters for the P-
glycoprotein substrates. (a) Computed primary physico-chemical
parameters for Group A compounds (filled bars) versus Group B
compounds (unfilled bars). (b) Corresponding computed Abraham physico-
chemical descriptors; (c) Experimentally determined membrane affinity (Log
KIAM) parameter for Group A and Group B compounds (Immobilised artificial
membrane, IAM, chromatography) compared to liposome multi-lamellar
vesicle partitioning (MLV partitioning). Compound specific data in Tables I
and III. For 3A and 3B, * indicates statistical difference at P < 0.05, §
indicates statistical difference at P < 0.01, ¶ indicates statistical difference at
P < 0.001.
a
b
c
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Intestinal Permeation of P-Gp Substrates: Impact
of P-Gp Knockout
In parallel with the IPML absorption studies we examined the
impact of Mdr1a/1b (−/−) knockout upon the intestinal per-
meation of our panel of compounds. We used an established
Ussing chamber model comprising ileal segments isolated
from the same mice as used in the IPML experiments.
Tissue viability of the intestinal segments was maintained
over the 3 h permeation experiments with no intestinal segment
displaying a drop in TEER greater than 10% from the initial
pre-dosing readings. Across all preparations we found no sig-
nificant difference (P > 0.05) in the TEER between the wild
type (Mdr1a/1b +/+) and knockout (Mdr1a/1b −/−) tissue, i.e.
respective TEER readings of 83 ± 21 Ω.cm2 and 79 ± 19
Ω.cm2. The lack of effect of P-gp deletion upon intestinal
TEER is consistent with the findings of Stephens et al. (21)
reporting no difference in the permeability of wild-type and
Mdr1a (−/−) mouse intestinal segments to mannitol; Mdr1a
being the more highly expressedMdr1 product in the intestine.
In contrast to the IPML data our studies with Mdr1a/1b
(−/−) knockout in intestinal tissue resulted in significantly in-
creased (P < 0.0001) permeabilities for both the Group A and
Group B compounds (Fig. 4a, Table III), with an average 2.8-
fold increase in permeability for the Group A compounds and
a 1.9-fold increase for the Group B compounds (Fig. 4b). In
keeping with the Group B compounds displaying a less polar
character (consistent with faster transmembrane movement)
these compounds showed a significantly greater (P = 0.02) per-
meability than the Group A compounds in the WT Mdr1a/1b
(+/+) intestinal tissue, a difference that was however abolished
with the Mdr1a/1b knockout (P > 0.05) (Fig. 4a). This suggests
in the absence of P-gp a near comparable intestinal permeabil-
ity between the Group A and B compounds, but in the pres-
ence of P-gp the intestinal permeability of the Group A com-
pounds is more susceptible to P-gp-mediated efflux. The dis-
parity in outcomes between the lung and intestinal models is
exemplified in Fig. 4b where in the lung it is the absorption of
the Group B compounds only that are affected (increased) by
P-gp knockout, while in the intestine the permeability of both
sets of compounds are increased, although here the Group A
compounds appeared to be affected to a greater extent.
Figure 4c shows for the 18 compound panel the rank order
relationship between LogKIAM (x-axis) and the impact of P-gp
knockout upon intestinal permeability (y-axis). A strong nega-
tive correlation (Spearman ’s Coefficient − 0.800,
P= 0.00004) was observed with the inference that compounds
with a lower membrane affinity are more susceptible to P-gp-
mediated efflux in the intestine, and vice versa; substituting
LogKIAM with the MLV partitioning parameter produced a
similar trend.When LogKIAM is substituted for the rank order
of compound intestinal permeation in the WT Mdr1a/1b
(+/+) mice (x-axis) a similar strong negative correlation
(Spearman’s Coefficient − 0.864, P = 0.000004) is obtained
(Fig. 4d). Both Fig. 4c and d show for the intestinal tissue the
tendency for the more polar Group A substrates to be affected
to a greater extent by P-gp.
It should be noted that while all Group A and B com-
pounds showed a consistent trend for increased permeation
across the intestinal tissue of the knockout mice the data for
two of the Group B compounds, GSK3 and salmeterol, failed
to reach statistical significance (P > 0.05) (Table III). These
compounds are represented in Fig. 4c and d as those falling
below the horizontal dashed line. The reason for this is un-
clear although not inconsistent with accepted understanding,
i.e., GSK3 possesses one of the most non-polar physico-chem-
ical profiles within the panel as a whole, and together, GSK3
and salmeterol display the greatest membrane interactions in
one or other of this study’s membrane affinity/MLV
partitioning experiments (Table II).
Figure 4e and f show comparative correlation plots for the
IPML experiments. Here no relationship was seen between
the rank order LogKIAM and the impact upon IPML perme-
ability arising from P-gp knockout (Fig. 4e); substituting
LogKIAM with the MLV partitioning produced a similar
trend. A lack of correlation was also evident where the
LogKIAM data (x-axis) was replaced by the rank order for
compound permeation in the WT Mdr1a/1b (+/+) lungs
(Fig. 4f). Figure 4e and f highlight again that it is only the
Group B compounds, i.e. those displaying a less polar charac-
ter, whose permeation in the lung is affected by P-gp.
Lung Retention of P-Gp Substrates
Figure 5 shows for the Group B compounds the % of depos-
ited dose associated with the lung tissues at the end of the
IPML experiments; the data was determined by mass balance
calculations accounting for drug remaining in the dosing sy-
ringe and tracheal cannula, and the mass of compound
absorbed to the perfusate. The lung retention data highlights
significant (P < 0.05) differences for each of the Group B
compounds between Mdr1a/1b (+/+) WT and Mdr1a/1b
(−/−) KO mice. While such differences in lung retention be-
tween the P-gp phenotypes are significant across the Group B
compounds as a whole they account for modest changes. For
example, with respect to those inhaled molecules within our
panel the absolute difference between the% of deposited dose
retained in the WT versus the KO lungs ranged from 16% for
GSK2 (i.e. 74.5% - 58.3%) to 6% for salbutamol (i.e. 75.5% -
69.5%). However even comparatively small differences re-
ported in the context of the current experimental design
may become more noteworthy in a clinical setting.
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Fig. 4 Comparative impact ofMdr1a/1b (−/−) knockout upon P-glycoprotein substrate permeation in intestinal ileal segments (Ussing chamber) and the IPML
model. (a) Permeability of Group A compounds (filled bars) and Group B compounds (unfilled bars) across isolated mouse intestinal segments in WT (Mdr1a/1b
+/+) and KO (Mdr1a/1b−/−) mice. Data represent mean ± S.D. with n= 8 for Group A compounds and n= 10 for Group B compounds. Data for each
compound in any given Mdr1a/1b phenotype is derived from six to nine intestinal segments. Original data in Table III. *indicates statistical difference (P = 0.02)
between the Group A WT and Group B WT; (b) Mean fold-change in permeation arising from P-gp knockout, expressed as KO: WT ratio. Mean value
represented by horizontal line with associated 95% confidence interval. Also shown are the individual ratios for the Group A and B compounds for intestinal
permeation (ratios of Papp values, P>0.05) and for IPML absorption (ratios of AUC0–30 min values, P<0.05). Original data in Tables I (lung) and IV (intestine). For
clarity the intestinal ratio data for the Group A compound saquinavir (10.07) has been excluded. Its inclusion would result in an increase in the mean ratio for the
Group A (Intestine) data from 2.92 to 3.78 without changing the statistical inference; (c and d) Rank order correlations of the 18 P-gp substrates in the intestinal
Ussing chamber model where on the y-axis is plotted the compound rank order of the increasing impact of P-gp knockout upon intestinal permeability. A greater
rank indicates a greater impact of the KO phenotype on a compound’s permeation. On the x-axis is plotted: (c) the compound rank order for LogKIAM, where a
greater rank indicates a greater LogKIAM. (d) the compound rank order for intestinal Papp in WTMdr1a/1b (+/+) tissue, where a greater rank indicates a greater
permeation. Plots derived from data in Tables III and IV, respectively; (e and f) Rank order correlations of the 18 P-gp substrates in the IPMLmodel where on the y-
axis is plotted the compound rank order of the increasing impact of P-gp knockout upon IPML absorption (AUC0–30). On the x-axis is plotted: (e) the compound
rank order for LogKIAM; (f) the compound rank order for IPML absorption in WT Mdr1a/1b (+/+) tissue, where a greater rank indicates a greater absorption.
Plots derived from data in Tables II and III. In plots 4c to 4f those compounds below the horizontal dashed line failed to show a significant (P > 0.05) change in
permeation as a result of the KO, while those compounds above the line displayed a significant (P < 0.05) increase in permeation with the KO.
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Development of a QSAR Model to Predict Differential
Absorption of P-Gp Substrates in the IPML
To identify the principal physico-chemical determinant(s) un-
derpinning the functional differentiation between the Group
A and Group B P-gp substrates, and to build a predictive
model based on structure alone we undertook multivariate
analysis by constructing an orthogonal PLS Discriminant
Analysis (oPLS-DA) model comprising the 13 physico-
chemical properties for all 18 compounds (Table I).
We identified a comprehensive series of physico-chemical
descriptors that correlate with whether the compounds show a
differentiation in their pulmonary absorption in the IPML
model between Mdr1a/1b (+/+) WT and Mdr1a/1b (−/−)
KO mice. The fitted oPLS model (R2 = 059, Q2 = 0.53
n = 18) provided excellent separation between Group A and
Group B substrates with only one outlier, the Group A com-
pound acrivastine. The Scores Plot of the resulting oPLS
model (Fig. 6a) displays the relationships between the different
compounds; with Group A compounds represented by Blue
symbols and Group B compounds by Red symbols. Here
acrivastine, lying on the right hand side of the plot is shown
to be more closely related to the Group B compounds based
on the 13 physico-chemical descriptors (x-axis variables) used
to build the model, yet it is an outlier because it behaves as a
Group A compound in the IPML with its absorption unaffect-
ed by P-gp knockout.
The explanation as to what accounts for the separation
between the 18 compounds on the Scores Plot is highlighted
in the Loadings Plot (Fig. 6b). Again the attributed variability
is described by component 1 along the x-axis and therefore an
increasing magnitude in the values of the descriptors towards
the left of the plot are associated with characteristics of the
Group A compounds. Those descriptors positively correlated
Table III Permeability coefficients
(Papp) in the Ussing chamber model
using intestinal segments isolated
from either wild-type P-gp express-
ing (+/+) or P-gp knockout
(−/−)mice. The 18 substrates are
grouped into those compounds
whose absorption in the IPML was
unaffected by P-gp knockout
(Group A) or those compounds
whose absorption in the IPML was
increased by P-gp knockout (Group
B). Data represent the mean ± SD
of n = 8 intestinal segments
matched to the IPML experiments.
Statistical analysis for intestinal Papp
comparisons by unpaired T-test.
Across all experiments there was no
significant difference in the TEER
values between the wild-type P-gp
expressing (+/+) or P-gp knockout
mice (−/−) with, respectively
TEER = 83 ± 21 and 79 ± 19
Ω.cm2
Mdr1a/1b (+/+)
Permeability coefficient
cm/s (x10−6)
Mdr1a/1b (−/−)
Permeability coefficient
cm/s (x10−6)
P-value Ratio Permeability
(−/−): (+/+)
GROUP A Acrivastine 9.17 ± 2.87 14.32 ± 2.88 0.044 1.56
Digoxin 6.04 ± 1.46 20.94 ± 2.94 0.0001 3.47
Erythromycin 3.02 ± 1.15 13.70 ± 4.54 0.004 4.53
GSK1 3.13 ± 1.25 10.57 ± 3.23 0.005 3.38
Mitoxantrone 4.69 ± 1.06 13.70 ± 2.69 0.001 2.92
Monensin 10.9 ± 1.78 19.06 ± 2.41 0.002 1.74
Puromycin 5.83 ± 2.38 14.95 ± 2.33 0.002 2.56
Saquinavir 1.56 ± 0.69 15.73 ± 3.52 0.0002 10.07
GROUP B Chloroquine 14.95 ± 2.33 23.39 ± 4.18 0.012 1.56
Colchicine 6.93 ± 3.15 14.95 ± 3.18 0.012 2.16
Domperidone 10.78 ± 1.77 25.42 ± 8.04 0.012 2.36
Eletriptan 4.90 ± 2.51 11.04 ± 2.17 0.010 2.26
GSK2 8.18 ± 2.33 17.50 ± 2.91 0.002 2.14
GSK3 12.2 ± 2.25 15.31 ± 2.25 0.102 1.25
Indacaterol 15.2 ± 2.79 29.22 ± 4.40 0.002 1.92
Rh-123 9.06 ± 1.81 22.55 ± 2.24 0.0001 2.49
Salbutamol 10.6 ± 2.30 14.90 ± 2.16 0.034 1.41
Salmeterol 15.8 ± 2.16 18.33 ± 2.38 0.170 1.16
Fig. 5 Lung retention of Group B compounds. The % of lung deposited
dose retained in the IPML lungs of WT Mdr1a/1b (+/+) and KO Mdr1a/1b
(−/−) mice at the end of the 30 min IPML absorption experiments. Data
represent mean ± S.D., n= 4 to 6 mice for each treatment arm. * indicates
statistical difference at P< 0.05, § indicates statistical difference at P< 0.01, ¶
indicates statistical difference at P < 0.001.
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with Group A characteristics are those associated with in-
creased polarity, i.e. P-gp substrates more likely to display
lowermembrane affinity and reduced transmembrane perme-
ation rates, the very characteristics that would be indicative of
P-gp limiting substrate permeation in the intestine.
The statistical output from the oPLS model displayed a R2
of 0.59 and aQ2 (i.e. predictivity) of 0.53. Considering the low
number of observations upon which the model was built
(n = 18 compounds) the statistics are sufficient for a semi-
quantitative ranking and classification-based predictive
assessment.
The oPLS model was then used to predict whether 129
known P-gp substrates were likely to display characteristics
more like the Group A or Group B compounds. The 129
compounds, their physico-chemical properties and the
resulting oPLS model predictions are shown in full in
Supplementary Table S6. The vast majority of compounds
(101 out of 129) are predicted to be Group B like, i.e. sub-
strates that if administered into the lung would display pulmo-
nary absorption likely to be affected by P-gp. Within the panel
of 129 molecules was the P-gp substrate, loperamide, which
was forecast to behave as a Group B compound. Loperamide
was not part of the current 18 member panel of substrates but
in earlier independent IPRL investigations its pulmonary ab-
sorption was shown to be affected by P-gp (16).
DISCUSSION
Using lungs derived fromMdr1a/1b genetic knockout mice we
explored the impact of pulmonary P-gp upon the absorption
of an 18 member panel of P-gp substrates administered into
the airways of an isolated perfused mouse lung (IPML). Solely
on the basis of the impact of P-gp upon a substrate’s absorp-
tion within the IPML we defined the panel members as either
‘Group A’ compounds i.e. those whose pulmonary absorption
was unaffected by Mdr1a/1b knockout, or ‘Group B’ com-
pounds, i.e. those whose pulmonary absorption was limited by
P-gp, specifically absorption was increased by Mdr1a/1b
knockout. We explored if the physico-chemical properties of
these two groups of compounds were distinguishable. We
found the Group A compounds to possess a distinctly more
polar character and significantly lower phospholipid
Fig. 6 QSAR Modeling using
orthogonal PLS Discriminant
Analysis (oPLS-DA). (a): The Scores
plot from the resulting oPLS model
generated within SIMCA-P+ on the
18 P-gp substrates in our panel
showing differentiation between the
Group A and Group B compounds
based on their computed physico-
chemical properties. Group A
compounds represented by the
blue symbol, Group B by the red
symbol. (b): The Loadings plot from
the resulting oPLS model highlights
the contribution of each of the
physico-chemical descriptors to the
model components, with the
increasing magnitude in the values
of the descriptors towards the left of
the plot associated with Group A
characteristics.
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membrane affinities and transmembrane movement rates
compared to the Group B compounds.
To address if the Group A and B compounds could be
differentiated on the basis of intrinsic P-gp binding kinetics
we used artificial membrane models constituted by human
(MDR1) and mouse (both Mdr1a and Mdr1b) P-gp. Although
the quantitative nature of such in-vitro kinetic parameters
may not be directly translatable to the in-vivo barrier, the
results substantiated the similar and overlapping mouse
Mdr1a and Mdr1b (and indeed human MDR1) binding inter-
actions between the Group A and Group B compounds. We
also examined the interactions of the panel of P-gp substrates
with mouse Bcrp. Human (BCRP) and rodent (Bcrp) lungs have
been shown to express this transporter (3), with at least in
humans BCRP expression seen in alveolar pneumocytes (26)
but with little to no expression in bronchial epithelium (9,26).
We found only four of the 18 compounds (two from each of
Group A and Group B) to show evidence of Bcrp interactions,
the very four compounds where some literature evidence ex-
ists that supports such interactions either in the context of a
substrate or an inhibitor (27–30); the most recognised
BCRP/Bcrp substrate within our panel being mitoxantrone.
Importantly, in respect to Bcrp interactions there was no selec-
tive bias towards the Group A compounds, and as such we
consider potential Bcrp efflux in the lung per se was not a
determining factor responsible for the lack of effect of
Mdr1a/1b deletion to result in increased pulmonary absorp-
tion for the eight Group A compounds.
We next questioned how the differing physico-chemical
properties of the Group A and Group B compounds may
determine susceptibility to P-gp efflux in the lung compared
to the intestine. For the latter we used an Ussing chamber
model with isolated intestinal (ileal) segments derived from
the Mdr1a/1b knockout mice. We found the relationship be-
tween substrate physico-chemical properties and absorption
in the lung to be dissimilar to that evident in the intestine.
Namely, in the intestine it was the permeation of the more
polar P-gp substrates (Group A compounds) that was more
susceptible to the effects of P-gp efflux, a finding consistent
with previously defined relationships established in various
intestinal preparations (17,31,32). In contrast, in the lung the
absorption of the least polar substrates (Group B compounds)
was most affected by P-gp with the pulmonary absorption of
the Group A substrates remaining unaffected.
We suggest it is the interplay between the substrates’ differ-
ential physico-chemical properties coupled with the differing
nature of the absorption barriers which underpins the discor-
dant findings we report above: The initial step in the passive
transcellular permeation of a compound is its interaction with
the outer membrane leaflet. Themore non-polar a compound
the greater its affinity for membrane binding which will in-
crease the concentration of the compound in the outer mem-
brane leaflet; the donor ‘reservoir’ for the compound’s
transmembrane movement. As such increases in a com-
pound’s membrane affinity, while not the rate-limiting step,
may be predicted to increase a compound’s transmembrane
permeability rate (33,34). At least in the intestine it is apparent
that the effect of P-gp upon the passive transcellular perme-
ation of a substrate is influenced by the opposing consider-
ations of the intrinsic efficiency of P-gp to efflux the substrate
and the substrate’s passive transmembrane permeability rate
(17,31,32). Specifically, an increased passive transmembrane
permeability rate is associated with a reduced membrane
dwell time and a reduced net effect of P-gp upon a substrate’s
overall permeation. This same relationship also appears oper-
ative for membrane transport within induced MDR cell phe-
notypes (20,35). It also extends to subsets of P-gp substrates
whose transmembrane dwell time is so short that intestinal
transcellular permeation appears to be essentially uninflu-
enced by P-gp (36). The above understanding is consistent
with the intestinal data we report here. Indeed, our overall
findings do not challenge the above principle when this man-
ifestly applies to the process of transmembrane transport itself.
There are however some notable differences between the
intestinal and lung barriers that are relevant to the
interpretation of our data.
There is a general recognition that polar molecules admin-
istered into the lung airways show a greater permeation across
lung epithelium than across other epithelial barriers, a finding
considered to reflect a greater passive permeation through
paracellular pathways. This is substantiated by kinetic evi-
dence from a range of species, for an assortment of molecule
classes and by a number of different laboratories, for example
(13,37,38) and reviewed in (39–42). One such example is the
pulmonary absorption of mannitol and inulin, both absorbed
from the lung at a faster rate and to a greater extent (50% and
17% of administered dose, respectively) than from the small
intestine (<2%) (38). Another example is from the work of
Tronde et al. (13) reporting that compounds having low oral
permeability in the Caco-2 cell model (Papp values <1 x
10−6 cm/s), such as terbutaline, cromolyn and cyanocobala-
min, show high permeability across the lung. Indeed, there are
a number examples of polar compounds possessing a PSA
≥120 Å2 and recognised to display <10% oral absorption
but which nevertheless display >80% pulmonary
bioavailability.
A tentative model we therefore propose to explain our
results is represented in Fig. 7. Specifically, it considers the
following: a) less polar P-gp substrates will be predominantly
absorbed across a barrier by the passive transcellular route
and as such be exposed to plasma membrane P-gp; b) some
of these substrates will display a greater membrane affinity, a
higher transmembrane permeation rate and as such experi-
ence a lesser net effect of P-gp efflux, and vice versa; c) with
increasing substrate polarity the net effect of P-gp efflux will be
observed to increase as the substrate’s membrane dwell time is
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extended; d) as polarity increases further, however, then more
time will be required for the substrate to achieve high enough
concentrations in the membrane for the net effect of P-gp
efflux to be measured. Importantly a kinetic consequence of
this will be a greater proportion of the polar substrate avail-
able for passive absorption via the paracellular pathway
avoiding exposure to P-gp.
Applying the above to our data (Fig. 7) we may view the
intestine as a barrier with a more restrictive paracellular path-
way. Consequently, in the intestine there is reduced
paracellular transfer for the more polar P-gp substrates. As
such the net effect of P-gp upon overall intestinal absorption
will be seen to be greater for the more polar substrates (e.g.
Group A compounds such as digoxin) compared to the less
polar substrates (e.g. Group B compounds such as Rh-123).
For a barrier with an apparently less restrictive ‘leakier’
paracellular pathway (e.g. lung) a greater proportion of the
more polar P-gp substrates will be absorbed by the
paracellular route and avoid plasma membrane P-gp efflux.
As such the net effect of P-gp upon overall lung absorption will
be seen to be greater for the less polar substrates (i.e. Group
B). It is only when the same set of P-gp substrates are studied
across different absorption barriers will any such distinct
barrier-dependent physico-chemical requirements be
observed.
The question of how the relative expression levels of P-gp
between lung and intestinal barriers may impact our
interpretation warrants some comment. It is fair to conclude
from transcriptional and protein expression data (3–9) as well
in-vitro transport studies (reviewed in (1)), that functional P-gp
expression in lung epithelium will likely be significantly less
than in ileal enterocytes. However, a lower P-gp expression
in the lung barrier would not in its own right be the basis for
the differential and transposed physico-chemical relationships
we have observed in this current work. Indeed, regardless of
the expression level of P-gp it would remain true that the more
polar substrates if accessing the plasma membrane would be
those that remain most affected by P-gp. Although a reduced
P-gp level in any barrier would make less distinct the impact of
P-gp between polar and less polar substrates. In summary,
against a background of divergent paracellular properties be-
tween barriers the different levels of P-gp expression may
magnify to a lesser or greater extent the overall impact of P-
gp efflux upon barrier absorption, although the trend as
outlined in the scheme of Fig. 7 would remain generally
similar.
By applying multivariate analysis to the panel of 18 P-gp
substrates we identified a comprehensive series of physico-
chemical descriptors that correlate with whether the com-
pounds show a differentiation in their pulmonary absorption
in the IPML model between the Mdr1a/1b (+/+) WT and
Mdr1a/1b (−/−) KO mice. The main attributes of our mul-
tivariate approach, oPLS and its extension to oPLS-DA,
have been described elsewhere (43), with the attraction of
this method being its suitability for classification of data that
have multi-collinear and noisy variables. In particular the
oPLS-DA algorithm will model the discriminatory compo-
nents and the Y-orthogonal components separately, which
makes interpretation of the model straightforward as all the
information relating to the classification will be contained
along the x-axis of the Loadings plot. The oPLS model we
generated was used to predict whether 129 known P-gp sub-
strates if administered into lung airways would likely display
characteristics more like the Group A or the Group B com-
pounds. The vast majority of compounds (101 out of 129) are
predicted to be Group B like, i.e. substrates if administered
into the lung would display pulmonary absorption that would
be affected by P-gp. These oPLS model predictions included
eight P-gp substrates currently licenced as inhaled medicines:
the beta-adrenoreceptor agonists salbutamol, salmeterol,
indacaterol, and the glucocorticoids beclomethasone,
budesonide, ciclesonide, fluticasone and mometasone. All
eight were identified as fitting the profile for Group B
compounds. This current QSAR model in combination
with other QSAR models in this area (44) may collectively
predict from molecular structure alone both the extent of
pulmonary absorption and the impact of pulmonary P-gp.
As such these models advance our understanding of the im-
pact of P-gp in the airways relevant to profiling of inhaled
drug discovery candidates.
Fig. 7 Putative model of the combined impact of epithelial barrier
paracellular permeability and compound physico-chemical properties upon
the absorption of P-gp substrates: For a more restrictive paracellular pathway
(e.g. intestine, Solid line) P-gp efflux will have a greater net effect upon overall
barrier absorption for the more polar substrate(s) (Blue symbol - e.g. digoxin)
compared to the less polar substrate(s) (Red symbol - e.g. Rh-123).
Alternatively, for the barrier with a less restrictive ‘leakier’ paracellular pathway
(e.g. lung, Dashed line) P-gp efflux will have a greater net effect upon overall
barrier absorption for the less polar substrate(s) (Red symbol - e.g. Rh-123)
compared to the more polar substrate(s) (Blue symbol - e.g. Digoxin). A fold-
change of 1 (y-axis) is indicative of no net effect upon overall absorption arising
from the deletion of P-gp, i.e. P-gp has no impact upon a substrate’s overall
absorption.
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For inhaled locally acting drugs it is the impact of an efflux
mechanism upon intra-luminal pulmonary disposition and
unbound concentrations in local tissue compartments and ep-
ithelial lining fluid (ELF) that will be of relevance in local PK-
PD relationships (1,45). The complexities regulating intra-
pulmonary kinetics, exemplified by inhaled corticosteroids,
are the subject of notable commentaries by Derendorf and
Hochaus (46–48). In the current work we determined P-gp
to increase the lung retention for some inhaled drugs/drug
candidates by up to 16% of the deposited dose. However,
even such comparatively small increases in the context of the
current short (30 min) experimental design may become more
noteworthy in a clinical setting. For example, the impact of P-
gp-mediated efflux upon substrate intra-luminal concentra-
tions will become progressively more significant as local con-
centrations decrease at later time points following inhaled ad-
ministration. Indeed the dosage indications for most of the
inhaled glucocorticoids are suggestive that initial concentra-
tions in human ELF maybe sufficiently high so as to partially
overcome a potential P-gp efflux capacity.
In this context we rule out any potential saturation of P-gp
within the IPML as the basis for the lack of effect of P-gp upon
the pulmonary absorption of the Group A substrates. Simply,
all non-radiolabelled compounds (be they Group A or B com-
pounds) were administered at equivalent doses estimated to
achieve an initial indicative concentration in the IPML ELF
approximating 25 μM. These same concentrations were used
in the intestinal Ussing chamber studies. We also found no
distinction in the Mdr1a/Mdr1b binding kinetics between the
two groups. Further, the archetype Group A compound, di-
goxin, was delivered at a radiolabel dose of 16 pmoles, equat-
ing to an estimated initial concentration in ELF approximat-
ing 0.3 μM. Neither should respiratory mucus be viewed as
the basis of the differential outcomes we found. Mucus com-
prises amongst other elements a high proportion of water and
mucin glycoprotein polymer, the fibres of which form a fibril-
lar network with inter-fibre water-filled pores in the 100 nm
range (49). While mucus represents a permeability barrier to
macromolecules or supramolecular entities, through physical
size restriction and hydrophobic and ionic interactions, small
molecules such as those in the current study are less prone to
suffer diffusional hindrance within the mucus barrier.
We undertook a pilot in-vivo experiment dosing to wild-
type (Mdr1a/1b +/+) and knockout (Mdr1a/1b −/−) mice the
archetype compounds, digoxin and Rh-123, via intra-nasal
instillation; a route delivering a significant fraction of dose to
the respiratory tract (see Supplementary Pilot In-vivo experi-
ment). Consistent with the IPML study, and in agreement
with Shanker’s digoxin lung clearance data (50), the clearance
of digoxin from the in-vivo mouse lungs was rapid with digox-
in lung levels similar between the wild-type and knockoutmice
at 1 h post-instillation, but undetectable thereafter. Indeed, it
is the lung clearance profiles that may be more reliable and
informative following the intra-nasal instillation dosing. For
Rh-123 we measured lung levels up to 12 h post-instillation.
The bi-exponential Rh-123 lung clearance curves displayed a
t1/2 for the initial decline (over the first 3 h) that was slower
(t1/2 136 min) in WT animals than in KO animals (t
1/2
107 min), thereafter the terminal decline phase was similar
but more prolonged (t1/2 500 min) in both the WT and KO
animals. Cationic lipophilic drugs such as Rh-123 tend to
accumulate in the lungs to form slowly eluting pools (51,52).
One interpretation of our pilot data is that the initial more
rapid decline phase represents loss of Rh-123 from the airways
across lung epithelium to blood, a process influenced by P-gp
in the airway epithelium. The slower terminal phase repre-
sents loss of Rh-123 from slowly eluting pools in the lung
parenchyma, with Rh-123 having previously passed across
the airway epithelium this clearance phase is not subject to
P-gp effects. The pilot study shows some encouragement for
conducting a fuller in-vivo investigation particularly when
aligned to studying the potential impact of pulmonary P-gp
efflux upon efficacy and duration of action.
This current study has focussed on P-gp efflux from the
lung epithelium to airway lumen, however Roerig et al. (53)
proposed P-gp to serve as a barrier limiting uptake of the P-gp
substrate rhodamine 6G into the lung from blood. In our own
preparative IPRL and IPML experiments we found no evi-
dence of P-gpmediated efflux limiting uptake to the lung from
the perfusate for either Group A or Group B compounds.
This is consistent with in-vivo whole body disposition studies
reported inMdr1 knockout mice (54–57) where, following i.v.
or oral dosing routes, the lung to blood distribution ratios for
those P-gp substrates so far studied indicateMdr1 knockout to
have no significant impact upon lung accumulation.
Nevertheless, this area warrants further study particularly giv-
en the potential role that lung P-gp may have in modulating
drug-induced toxicities arising from systemic administration.
CONCLUSION
We have demonstrated that pulmonary P-gp is functional in
an intact lung impeding the absorption and increasing the
lung retention of a subset of P-gp-substrates administered in
the airways. Multivariate analysis identified a comprehensive
series of physico-chemical descriptors that correlate with
whether the absorption of a substrate will be affected by P-
gp or not. The contribution of pulmonary P-gp to the lung
absorption of airway administered substrates appears to be
defined by a distinctly different physico-chemical relationship
than that observed in the intestine. The QSAR model built
upon the current dataset was used to predict the likelihood of
129 other known P-gp substrates undergoing P-gp-dependent
pulmonary disposition. Within this set were included
marketed pulmonary delivered drugs, of which there were
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eight and all of which were predicted to display P-gpmediated
modulation in their pulmonary absorption. The research ad-
vances our understanding of the impact of P-gp in the airways
relevant to profiling of inhaled drug discovery candidates. The
findings also highlight a potential for P-gp mediated pulmo-
nary disposition in the clinic.
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